Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ASCO GU 2022: Prostate roundup
Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore
ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )
20 Apr 2022
Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy...
Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda, Madr...
Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy in NSCLC ( Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain )
31 Mar 2022
ASCO GU 2022: Latest in mHSPC
Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith
ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )
8 Mar 2022
Cancer nursing in India: Tumour lysis syndrome
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Cancer nursing in India: Tumour lysis syndrome ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )
28 Feb 2022
Latest developments in mHSPC
Prof Kurt Miller and Prof Laura-Maria Krabbe
Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )
25 Feb 2022
ASCO GU 2022: The latest in CRPC, including PARP combo data
Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Mers...
ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )
25 Feb 2022
Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL
Dr Juliana Pereira & Dr Steven Horwitz
Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL ( Dr Juliana Pereira & Dr Steven Horwitz )
22 Feb 2022
Maintenance PARP inhibition following chemotherapy for metastatic urothelial car...
Dr Simon Crabb - University of Southampton, Southampton, UK
Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma ( Dr Simon Crabb - University of Southampton, Southampton, UK )
21 Feb 2022
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Feb 2022
Update on the new EUSOMA quality indicators for breast cancer
Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
Update on the new EUSOMA quality indicators for breast cancer ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )
3 Feb 2022
The optimal approach after neoadjuvant treatment: The Lucerne toolbox
Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
The optimal approach after neoadjuvant treatment: The Lucerne toolbox ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )
3 Feb 2022
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC
Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
20 Jan 2022